Takeda

Takeda investors mount last-minute effort to stymie Shire deal: FT
Takeda investors mount last-minute effort to stymie Shire deal: FT
Fierce Pharma
Takeda
Shire
shareholders
M&A
Flag link:
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
Endpoints
Takeda
Shire
M&A
Christophe Weber
Flag link:
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Channel News Asia
Takeda
Shire
M&A
Europe
Flag link:
Takeda CEO confident about Shire merger
Takeda CEO confident about Shire merger
Pharmaforum
Takeda
Shire
M&A
shareholders
Pharma CEOs
Christophe Weber
Flag link:
Positive quarter from Takeda, waiting for completion of Shire deal
Positive quarter from Takeda, waiting for completion of Shire deal
GoinPharma
Takeda
Shire
M&A
earnings
Flag link:
Takeda considering sale of OTC business in Europe ($11bn)
Takeda considering sale of OTC business in Europe ($11bn)
Bloomberg
Takeda
Shire
M&A
OTC
Flag link:
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Flag link:
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
Flag link:
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
CP Wire
Enterome
Takeda
Crohn's Disease
EB8018
Flag link:
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Enterome
Takeda
Crohn's Disease
EB8018
Flag link:
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Fierce Pharma
Shire
FDA
Takeda
M&A
Flag link:
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
CP Wire
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Flag link:
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Flag link:
Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma
Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma
BioSpace
Seattle Genetics
Takeda
Adcetris
peripheral T-cell lymphoma
Flag link:
Disgruntled Takeda alums demand a window into $62B Shire buy
Disgruntled Takeda alums demand a window into $62B Shire buy
Fierce Pharma
Takeda
Shire
M&A
Flag link:
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
CP Wire
Seattle Genetics
Takeda
Adcetris
T-cell lymphoma
Flag link:
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
Seattle Genetics
Takeda
Adcetris
T-cell lymphoma
Flag link:
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
CP Wire
Takeda
Alunbrig
non-small cell lung cancer
Flag link:
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Takeda
Alunbrig
non-small cell lung cancer
Flag link:
Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run
Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run
Endpoints
Molecular Templates
Takeda
Multiple Myeloma
Flag link:

Pages